- Home
- BIIB vs HBAN Comparison
BIIB vs HBAN Comparison
Compare BIIB & HBAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- HBAN
- Stock Information
- Founded
- BIIB 1978
- HBAN 1866
- Country
- BIIB United States
- HBAN United States
- Employees
- BIIB N/A
- HBAN N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- HBAN Major Banks
- Sector
- BIIB Health Care
- HBAN Finance
- Exchange
- BIIB Nasdaq
- HBAN Nasdaq
- Market Cap
- BIIB 18.8B
- HBAN 25.6B
- IPO Year
- BIIB 1991
- HBAN N/A
- Fundamental
- Price
- BIIB $127.50
- HBAN $16.56
- Analyst Decision
- BIIB Buy
- HBAN Buy
- Analyst Count
- BIIB 27
- HBAN 20
- Target Price
- BIIB $188.17
- HBAN $18.32
- AVG Volume (30 Days)
- BIIB 1.2M
- HBAN 30.0M
- Earning Date
- BIIB 07-31-2025
- HBAN 07-18-2025
- Dividend Yield
- BIIB N/A
- HBAN 3.71%
- EPS Growth
- BIIB 26.39
- HBAN 17.13
- EPS
- BIIB 10.12
- HBAN 1.30
- Revenue
- BIIB $9,816,400,000.00
- HBAN $7,104,000,000.00
- Revenue This Year
- BIIB N/A
- HBAN $17.45
- Revenue Next Year
- BIIB N/A
- HBAN $5.28
- P/E Ratio
- BIIB $12.69
- HBAN $12.85
- Revenue Growth
- BIIB 1.59
- HBAN 5.17
- 52 Week Low
- BIIB $110.04
- HBAN $11.92
- 52 Week High
- BIIB $236.48
- HBAN $18.45
- Technical
- Relative Strength Index (RSI)
- BIIB 45.02
- HBAN 48.43
- Support Level
- BIIB $132.37
- HBAN $17.35
- Resistance Level
- BIIB $137.84
- HBAN $17.65
- Average True Range (ATR)
- BIIB 4.12
- HBAN 0.33
- MACD
- BIIB 0.01
- HBAN -0.05
- Stochastic Oscillator
- BIIB 25.82
- HBAN 26.99
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About HBAN Huntington Bancshares Incorporated
Huntington is a regional US bank with around $200 billion in assets (as of 2024) and has a large presence, particularly in the Midwestern market. It offers a full suite of consumer deposit and lending services, along with commercial services focused on payments, investment management, capital markets, equipment financing, treasury management, and other common banking services.